Jimmy Chang – Chairman & CEO, TaiMed Biologics
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Address: 18201 Von Karman Ave, Suite 470. Irvine, CA 92612
Tel: (949) 769-6543
Web: http://www.taimedbiologics.com/
TaiMed Biologics was formed on September 4, 2007 to realize the vision of creating a world-class, innovation-based biotechnology company that will satisfy the unmet medical needs of patients around the world.
The company signed an agreement with Genentech for the licensing of Ibalizumab shortly after its formation. This drug candidate, also known as TMB-355, is a proprietary humanized anti-CD4 monoclonal antibody for the treatment of HIV/AIDS. A phase-2b clinical trial is currently underway and the coma expect the trial to be completed in Q1 2011.
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of…
Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific…
Grace Yeh, Founder, President, and CEO of PharmaEngine, one of the most eye-catching success stories to recently emerge from Taiwan’s maturing biopharmaceutical sector, documents the main success factors that have…
Du-Shieng Chien, President & CEO of TaiRx, a Taiwan-based biopharmaceutical company focused on unmet medical needs, provides insights into the recent development of CVM 1118, a revolutionary cancer treatment targeting…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with…
In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to…
The past three years have been some of the most eventful in memory for Taiwan’s life sciences industry. At this year’s Bio Taiwan exhibition, the annual conference that invites…
The Chairman and CSO of TCM Biotech offer perspectives on the potential of botanical drugs, and chart their biotech company’s trajectory in bringing these drugs to both the Chinese and…
The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how…
The minister in charge of medical tourism in Taiwan speaks about the country’s advantages over its Asian neighbours, and how the new era of Taiwan’s medical services will…
Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars…
See our Cookie Privacy Policy Here
